COVID-19 is a global pandemic and fighting this will take a major global effort investigating many prevention therapies, treatment options and new modalities. We believe that our SynRGY platform is well-suited to develop novel vaccines for coronaviruses in combination with Immunomic Therapeutics' UNITE technology.
Currently, there is a high unmet need for preventative treatments for some Flaviviruses, including both Zika virus and Dengue viruses. While several vaccine candidates exist, the primary focus has been on eliciting neutralizing antibody responses. While antibodies play a critical role in protection, suboptimal responses can lead to exacerbation of disease during subsequent infections in a process known as antibody-dependent enhancement. We are focused on new methods of eliciting strong, protective T cell responses using our proprietary, RNA-based gene delivery platform.
Our team has worked for several years with the Shresta Laboratory at La Jolla Institute to develop vaccines that generate comprehensive immune responses to emerging infectious diseases including Flaviviruses.
Our team works with Immunomic Therapeutics and other undisclosed partners to advance candidates for infectious diseases with high unmet need.